RU2009114508A - Композиции и способы для регуляции развития сосудов - Google Patents
Композиции и способы для регуляции развития сосудов Download PDFInfo
- Publication number
- RU2009114508A RU2009114508A RU2009114508/15A RU2009114508A RU2009114508A RU 2009114508 A RU2009114508 A RU 2009114508A RU 2009114508/15 A RU2009114508/15 A RU 2009114508/15A RU 2009114508 A RU2009114508 A RU 2009114508A RU 2009114508 A RU2009114508 A RU 2009114508A
- Authority
- RU
- Russia
- Prior art keywords
- pathological condition
- antiangiogenic agent
- neoplasm
- administering
- individual
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 230000001575 pathological effect Effects 0.000 claims abstract 8
- 239000004037 angiogenesis inhibitor Substances 0.000 claims abstract 6
- 102100032031 Epidermal growth factor-like protein 7 Human genes 0.000 claims abstract 4
- 101000921195 Homo sapiens Epidermal growth factor-like protein 7 Proteins 0.000 claims abstract 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract 4
- 230000033115 angiogenesis Effects 0.000 claims abstract 4
- 239000005557 antagonist Substances 0.000 claims abstract 4
- 208000035269 cancer or benign tumor Diseases 0.000 claims abstract 4
- 230000002401 inhibitory effect Effects 0.000 claims abstract 4
- 201000009030 Carcinoma Diseases 0.000 claims abstract 2
- 239000002246 antineoplastic agent Substances 0.000 claims abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 230000002708 enhancing effect Effects 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Способ повышения эффективности противоангиогенного средства у индивидуума со связанным с ангиогенезом патологическим состоянием, предусматривающий введение индивидууму антагониста EGFL7 в сочетании со способным ингибировать ангиогенез противоангиогенным средством, тем самым усиливая указанную ингибирующую активность противоангиогенного средства. ! 2. Способ по п.1, где антагонист EGFL7 представляет собой антитело к EGFL7. ! 3. Способ по п.1, где патологическое состояние представляет собой новообразование. ! 4. Способ по п.3, где новообразование представляет собой карциному. ! 5. Способ по п.1, где патологическое состояние связано с глазом. ! 6. Способ по п.5, где патологическое состояние представляет собой внутриглазное неоваскулярное заболевание. ! 7. Способ по п.4, дополнительно предусматривающий введение химиотерапевтического средства.
Claims (7)
1. Способ повышения эффективности противоангиогенного средства у индивидуума со связанным с ангиогенезом патологическим состоянием, предусматривающий введение индивидууму антагониста EGFL7 в сочетании со способным ингибировать ангиогенез противоангиогенным средством, тем самым усиливая указанную ингибирующую активность противоангиогенного средства.
2. Способ по п.1, где антагонист EGFL7 представляет собой антитело к EGFL7.
3. Способ по п.1, где патологическое состояние представляет собой новообразование.
4. Способ по п.3, где новообразование представляет собой карциному.
5. Способ по п.1, где патологическое состояние связано с глазом.
6. Способ по п.5, где патологическое состояние представляет собой внутриглазное неоваскулярное заболевание.
7. Способ по п.4, дополнительно предусматривающий введение химиотерапевтического средства.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56205404P | 2004-04-14 | 2004-04-14 | |
| US60/562,054 | 2004-04-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006140081/13A Division RU2365382C2 (ru) | 2004-04-14 | 2005-04-14 | Композиции и способы для регуляции развития сосудов |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009114508A true RU2009114508A (ru) | 2010-10-27 |
Family
ID=35355481
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006140081/13A RU2365382C2 (ru) | 2004-04-14 | 2005-04-14 | Композиции и способы для регуляции развития сосудов |
| RU2009114508/15A RU2009114508A (ru) | 2004-04-14 | 2009-04-16 | Композиции и способы для регуляции развития сосудов |
| RU2013146239/15A RU2013146239A (ru) | 2004-04-14 | 2013-10-16 | Композиции и способы для регуляции развития сосудов |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006140081/13A RU2365382C2 (ru) | 2004-04-14 | 2005-04-14 | Композиции и способы для регуляции развития сосудов |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013146239/15A RU2013146239A (ru) | 2004-04-14 | 2013-10-16 | Композиции и способы для регуляции развития сосудов |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20070031437A1 (ru) |
| EP (1) | EP1734998A2 (ru) |
| JP (3) | JP5599136B2 (ru) |
| KR (1) | KR101227817B1 (ru) |
| CN (2) | CN1997394B (ru) |
| AU (1) | AU2005249377A1 (ru) |
| BR (1) | BRPI0509420A (ru) |
| CA (1) | CA2563445C (ru) |
| IL (2) | IL178329A0 (ru) |
| MX (1) | MXPA06011851A (ru) |
| NZ (1) | NZ550110A (ru) |
| RU (3) | RU2365382C2 (ru) |
| WO (1) | WO2005117968A2 (ru) |
| ZA (1) | ZA200608615B (ru) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0509420A (pt) | 2004-04-14 | 2007-09-04 | Genentech Inc | método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico |
| AR059851A1 (es) * | 2006-03-16 | 2008-04-30 | Genentech Inc | Anticuerpos de la egfl7 y metodos de uso |
| JP5437797B2 (ja) | 2006-06-12 | 2014-03-12 | サイトス バイオテクノロジー アーゲー | Ｒｎａバクテリオファージのウイルス様粒子にオリゴヌクレオチドをパッケージ化するための方法 |
| WO2008010986A2 (en) * | 2006-07-17 | 2008-01-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of modulating angiogenesis |
| WO2008130719A1 (en) * | 2007-04-24 | 2008-10-30 | University Of Louisville | Therapeutic beta-glucan combinations |
| JP2009005584A (ja) * | 2007-06-26 | 2009-01-15 | Miyazaki Prefecture | ゲル化剤、凍結保存剤、細胞保存用容器、細胞の凍結保存方法、細胞の融解方法、哺乳動物の細胞 |
| US9549971B2 (en) * | 2008-01-14 | 2017-01-24 | Genentech, Inc. | Methods for inhibiting angiogenesis using EGFL8 antagonists |
| WO2010034155A1 (zh) * | 2008-09-25 | 2010-04-01 | 中南大学湘雅医院 | 一种通过检测样品中eglf7来诊断肝细胞癌的试剂盒 |
| BRPI1007706A2 (pt) * | 2009-05-08 | 2019-04-02 | Genentech, Inc. | anticorpo anti-egfl7, anticorpo biespecífico, ácido nucléico, vetor, célula hospedeira, composição, método para produzir um anticorpo anti-egfl7, método de redução ou inibição da angiogênese em um indivíduo, método de acentuação da eficácia de um agente antiangiogênese em um indivíduo e método de redução ou inibição da perfusão e permeabilidade de um tumor em um indivíduo |
| RU2412251C1 (ru) * | 2009-06-15 | 2011-02-20 | Юрий Леонидович Дорохов | Антитело против фактора роста эндотелия сосудов и способ продукции антитела в растении |
| US20110076271A1 (en) * | 2009-07-13 | 2011-03-31 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| KR20190067275A (ko) * | 2009-12-21 | 2019-06-14 | 제넨테크, 인크. | 항체 제제 |
| WO2013061112A1 (en) | 2011-10-24 | 2013-05-02 | Centre National De La Recherche Scientifique | Use of egfl7 modulators for promoting or inhibiting migration of immune cells across vascular endothelium |
| WO2013142961A1 (en) * | 2012-03-27 | 2013-10-03 | London Health Sciences Centre Research Inc. | Egfl7 targeting and/or binding polypeptides and methods for inhibiting angiogenesis |
| WO2015077643A2 (en) * | 2013-11-21 | 2015-05-28 | Mfr Products, Inc. | Therapeutic device to assist in myofascial release, and method of use |
| UA123763C2 (uk) * | 2014-10-23 | 2021-06-02 | Енджіем Байофармасьютикалз, Інк. | Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19 |
| CN105543183B (zh) * | 2016-01-08 | 2019-04-12 | 吴帆 | 人肝癌细胞Egfl8基因过表达慢病毒在制备治疗肝癌药物中的应用 |
| EP3615075A4 (en) | 2017-04-24 | 2021-01-20 | Ohio State Innovation Foundation | RECOMBINANT EGFL7, ANTI-EGFL7 ANTIBODIES, AND THEIR USES |
| RU2678200C1 (ru) * | 2018-07-27 | 2019-01-24 | Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии" | Лекарственная пленка пролонгированного действия и способ её получения |
| WO2022025783A1 (ru) | 2020-07-28 | 2022-02-03 | Общество с ограниченной ответственностью "Ангиолайф" | Применения комбинации генов ангиогенных и нейротрофических факторов |
| CN114410642B (zh) * | 2021-12-31 | 2023-01-17 | 苏州大学 | 一种急性t淋巴细胞白血病药物靶点及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU597323B2 (en) * | 1985-11-22 | 1990-05-31 | Teijin Limited | Angiogenic factor derived from blood vessel endothelial cells |
| JPH01503705A (ja) | 1986-08-18 | 1989-12-14 | ビオタ・シャンティフィック・マネージメント・ピーティーワイ・リミテッド | 脈管形成の刺激および内皮化の増進 |
| RU2194528C2 (ru) * | 1996-05-31 | 2002-12-20 | Дзе Скриппс Рисерч Инститьют | Способы и композиции, используемые для ингибирования ангиогенеза |
| WO2002008284A2 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| WO2000053752A2 (en) | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
| US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030166907A1 (en) * | 1997-06-18 | 2003-09-04 | Zymogenetics, Inc. | Mammalian neuro-growth factor like protein |
| AU737132B2 (en) * | 1997-06-18 | 2001-08-09 | Zymogenetics Inc. | Mammalian neuro-growth factor like protein |
| US5972338A (en) | 1997-09-19 | 1999-10-26 | Genentech, Inc. | Tie ligands homologues |
| US20030166110A1 (en) | 1997-09-18 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7105640B2 (en) | 1997-10-17 | 2006-09-12 | Genentech, Inc. | Anti-pro792 antibodies |
| US20030199436A1 (en) | 1997-10-17 | 2003-10-23 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6974696B2 (en) | 1997-10-17 | 2005-12-13 | Genentech, Inc. | PRO853 nucleic acids |
| US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| US20030069178A1 (en) | 1997-10-17 | 2003-04-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030039648A1 (en) | 1998-09-16 | 2003-02-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
| US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
| US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
| US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
| ES2312205T3 (es) * | 1998-03-10 | 2009-02-16 | Genentech, Inc. | Nuevo polipeptido y acidos nucleicos que lo codifican. |
| US7371836B2 (en) | 1998-03-27 | 2008-05-13 | Genentech, Inc. | PRO526 nucleic acids |
| US7202338B2 (en) | 1998-03-31 | 2007-04-10 | Genentech, Inc. | PRO731 polypeptides |
| US7196176B2 (en) | 1998-04-01 | 2007-03-27 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6962797B2 (en) | 1998-04-15 | 2005-11-08 | Genentech, Inc. | Nucleic acids encoding PRO615 |
| DE19817946A1 (de) | 1998-04-17 | 1999-10-21 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Uterus-Normalgewebe |
| AU3965799A (en) | 1998-04-23 | 1999-11-08 | Millennium Pharmaceuticals, Inc. | Novel molecules of the t125-related protein family and uses thereof |
| US7067636B2 (en) | 1998-05-06 | 2006-06-27 | Genentech, Inc. | Anti-pro 1017 antibodies |
| US20030186368A1 (en) | 1998-05-13 | 2003-10-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
| US7019115B2 (en) | 1998-05-22 | 2006-03-28 | Genentech, Inc. | Pro1017 polypeptides |
| US7220835B2 (en) | 1998-07-30 | 2007-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP1135494A2 (en) | 1998-12-11 | 2001-09-26 | Incyte Pharmaceuticals, Inc. | Neuron-associated proteins |
| US20030187196A1 (en) | 1998-12-30 | 2003-10-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2383592A1 (en) | 1999-03-31 | 2000-10-05 | Curagen Corporation | 2384891 acids including open reading frames encoding polypeptides; orfx |
| WO2000063756A1 (en) | 1999-04-16 | 2000-10-26 | Fujikin Incorporated | Parallel bypass type fluid feeding device, and method and device for controlling fluid variable type pressure system flow rate used for the device |
| US7214656B2 (en) | 1999-04-28 | 2007-05-08 | Genentech, Inc. | PRO792 polypeptides |
| WO2001002563A2 (en) | 1999-07-02 | 2001-01-11 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| US7589172B2 (en) | 1999-07-20 | 2009-09-15 | Genentech, Inc. | PRO256 polypeptides |
| TWI265167B (en) | 1999-11-29 | 2006-11-01 | Akzo Nobel Nv | 3-methylene steroid derivatives |
| EP1285084A1 (en) | 2000-01-25 | 2003-02-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US7193050B2 (en) | 2000-02-18 | 2007-03-20 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2412211A1 (en) | 2000-06-23 | 2002-01-03 | Genetech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US7115415B2 (en) | 2000-09-15 | 2006-10-03 | Genentech, Inc. | PRO9821 nucleic acids |
| US7205392B2 (en) * | 2001-02-05 | 2007-04-17 | Innoventus Project Ab | Histidine-rich glycoprotein |
| US20030224984A1 (en) * | 2001-06-20 | 2003-12-04 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US20030100497A1 (en) | 2001-06-20 | 2003-05-29 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US20030023042A1 (en) | 2001-12-06 | 2003-01-30 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| FR2851249A1 (fr) * | 2003-02-17 | 2004-08-20 | Commissariat Energie Atomique | Nouveau facteur soluble secrete par les cellules endotheliales des vaisseaux sanguins, capable d'inhiber le recrutement des cellules perivasculaires du type musculaire lisse et ses applications |
| BRPI0509420A (pt) * | 2004-04-14 | 2007-09-04 | Genentech Inc | método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico |
-
2005
- 2005-04-14 BR BRPI0509420-8A patent/BRPI0509420A/pt not_active IP Right Cessation
- 2005-04-14 KR KR1020067021268A patent/KR101227817B1/ko not_active Expired - Fee Related
- 2005-04-14 MX MXPA06011851A patent/MXPA06011851A/es active IP Right Grant
- 2005-04-14 AU AU2005249377A patent/AU2005249377A1/en not_active Abandoned
- 2005-04-14 CN CN2005800195117A patent/CN1997394B/zh not_active Expired - Fee Related
- 2005-04-14 CA CA2563445A patent/CA2563445C/en not_active Expired - Fee Related
- 2005-04-14 ZA ZA200608615A patent/ZA200608615B/en unknown
- 2005-04-14 JP JP2007508646A patent/JP5599136B2/ja not_active Expired - Fee Related
- 2005-04-14 CN CN2012103813601A patent/CN102895663A/zh active Pending
- 2005-04-14 RU RU2006140081/13A patent/RU2365382C2/ru not_active IP Right Cessation
- 2005-04-14 EP EP05804788A patent/EP1734998A2/en not_active Ceased
- 2005-04-14 NZ NZ550110A patent/NZ550110A/en not_active IP Right Cessation
- 2005-04-14 WO PCT/US2005/013658 patent/WO2005117968A2/en not_active Ceased
-
2006
- 2006-09-27 IL IL178329A patent/IL178329A0/en active IP Right Grant
- 2006-10-12 US US11/546,760 patent/US20070031437A1/en not_active Abandoned
-
2009
- 2009-01-22 US US12/357,819 patent/US20090297512A1/en not_active Abandoned
- 2009-04-16 RU RU2009114508/15A patent/RU2009114508A/ru unknown
-
2010
- 2010-10-14 US US12/904,813 patent/US8790646B2/en not_active Expired - Fee Related
-
2011
- 2011-09-01 JP JP2011190733A patent/JP2011241230A/ja not_active Withdrawn
-
2013
- 2013-06-13 IL IL226899A patent/IL226899A0/en unknown
- 2013-09-24 JP JP2013196507A patent/JP2013256535A/ja not_active Withdrawn
- 2013-10-16 RU RU2013146239/15A patent/RU2013146239A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2365382C2 (ru) | 2009-08-27 |
| CN102895663A (zh) | 2013-01-30 |
| RU2006140081A (ru) | 2008-05-20 |
| IL178329A0 (en) | 2007-02-11 |
| IL226899A0 (en) | 2013-07-31 |
| CN1997394B (zh) | 2012-11-28 |
| US20090297512A1 (en) | 2009-12-03 |
| ZA200608615B (en) | 2008-05-28 |
| JP2007532685A (ja) | 2007-11-15 |
| US20120003208A1 (en) | 2012-01-05 |
| WO2005117968A2 (en) | 2005-12-15 |
| KR101227817B1 (ko) | 2013-01-29 |
| JP2013256535A (ja) | 2013-12-26 |
| JP2011241230A (ja) | 2011-12-01 |
| BRPI0509420A (pt) | 2007-09-04 |
| AU2005249377A1 (en) | 2005-12-15 |
| NZ550110A (en) | 2009-09-25 |
| JP5599136B2 (ja) | 2014-10-01 |
| WO2005117968A3 (en) | 2006-06-08 |
| CA2563445A1 (en) | 2005-12-15 |
| CA2563445C (en) | 2016-07-19 |
| RU2013146239A (ru) | 2015-04-27 |
| EP1734998A2 (en) | 2006-12-27 |
| US20070031437A1 (en) | 2007-02-08 |
| US8790646B2 (en) | 2014-07-29 |
| KR20070029687A (ko) | 2007-03-14 |
| MXPA06011851A (es) | 2006-12-14 |
| CN1997394A (zh) | 2007-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009114508A (ru) | Композиции и способы для регуляции развития сосудов | |
| EA200300528A1 (ru) | 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6 | |
| DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| EA200100731A1 (ru) | Фенилфенантридины с ингибирующей фдэ-4 активностью | |
| NO20044462L (no) | Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer | |
| ATE316795T1 (de) | Mesenchymale stammzellen für die prävention und behandlung von immunantworten bei transplantationen | |
| TR200103233T2 (tr) | Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri. | |
| ATE344029T1 (de) | Behandlung von typ ii diabetes mit dipeptidyl- peptidase-iv-hemmern | |
| EA200800879A1 (ru) | Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов | |
| DE69935853D1 (de) | Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten | |
| TNSN06138A1 (fr) | Inhibitors of the mutant form of kit | |
| RU2010133957A (ru) | Способы ингибирования ангиогенеза с помощью антагонистов egfl8 | |
| ATE476663T1 (de) | Spiegel der müllerschen inhibierenden substanz und ovarialreaktion | |
| RU2007149245A (ru) | Способ снижения риска развития рака и предраковой дисплазии | |
| ATE498403T1 (de) | Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren | |
| SG155901A1 (en) | Enzyme inhibitors and uses thereof | |
| CN109045013A (zh) | Nifuroxazide的医药新用途 | |
| BR0310030A (pt) | Espiral pertencente a uma turbomáquina | |
| MA27812A1 (fr) | Utilisation d'un inhibiteur de tyrosine kinase c-abl, pdgf-r ou c-kit dans le traitement du diabete | |
| ATE350101T1 (de) | Verwendung eines pyridazinon derivates zur behandlung des kongestiven herzversagens | |
| Simini | Proteins and pathogenesis of renal disease progression | |
| USD55818S (en) | Design for a portable lamp | |
| RU2000112238A (ru) | Способ лечения буллезной кератопатии | |
| Norqulov et al. | SOCIO-HYGIENIC FACTORS IN THE DEVELOPMENT OF CHRONIC LIVER DISEASES: A COMPREHENSIVE EPIDEMIOLOGICAL ANALYSIS | |
| FR2376664A1 (fr) | Derive l-prolinamide et son utilisation comme moyen therapeutique pour le traitement des maladies des yeux |